ICIs target inhibitory pathways in T-cells, such as the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) axes, thereby augmenting the anti-tumor immune response. Here, CTLA4 is linked to neoplasm.